A Phase I Multi-centre Trial of the Combination of Olaparib (PARP Inhibitor) and AZD5363 (AKT Inhibitor) in Patients With Advanced Solid Tumours
Phase of Trial: Phase I
Latest Information Update: 28 Feb 2017
Price : $35 *
At a glance
- Drugs Capivasertib (Primary) ; Olaparib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Acronyms ComPAKT
- 20 Apr 2016 Results (n=53) presented at the 107th Annual Meeting of the American Association for Cancer Research.
- 18 Apr 2016 Results published at the 2016 American Association for Cancer Research (AACR) Annual Meeting, as per AstraZeneca media release.
- 18 Apr 2016 Results published in AstraZeneca media release.